STOCK TITAN

Bio-Rad Laboratories, Inc. - BIO STOCK NEWS

Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.

Bio-Rad Laboratories, Inc. (NYSE: BIO) is a global leader in providing innovative tools and services to the life science research and clinical diagnostics markets. Established in 1952 and headquartered in Hercules, California, Bio-Rad boasts a robust network of operations spanning the globe, supported by a dedicated team of over 7,600 employees.

Bio-Rad's core business is segmented into two main areas: Clinical Diagnostics and Life Sciences. In the Clinical Diagnostics segment, which contributes to 56% of the company’s sales, Bio-Rad offers a range of test systems and specialized quality controls designed to ensure the accuracy and reliability of clinical laboratory results. These products play a critical role in patient care, enabling healthcare providers to make informed decisions.

The Life Sciences segment, accounting for 44% of sales, focuses on developing and manufacturing instruments and reagents used in research, biopharmaceutical production, and food testing. Bio-Rad is also a market leader in digital PCR (dPCR) technology, which is pivotal in genomics, proteomics, and drug discovery research.

Bio-Rad serves over 100,000 research and industry customers worldwide, fostering significant advancements in scientific research and development. The company has built strong partnerships and customer relationships that drive the introduction of new technologies in fields such as genomics, proteomics, drug discovery, food safety, and medical diagnostics.

Geographically, Bio-Rad's revenue distribution is diversified with 42% of sales from the Americas, 31% from Europe, 31% from Asia, and 6% from other regions, highlighting its extensive global reach.

One notable aspect of Bio-Rad's portfolio is its 33% ownership in Sartorius, a leading supplier of laboratory and bioprocessing solutions. Sartorius specializes in single-use technology for biologics manufacturing, thereby complementing Bio-Rad's offerings and enhancing its presence in the biopharmaceutical market.

With a strong legacy of innovation and a commitment to advancing scientific and medical research, Bio-Rad continues to lead in delivering high-quality, reliable solutions to its customers.

Rhea-AI Summary
Bio-Rad Laboratories, Inc. reports financial results for Q3 2023. Total net sales decreased by 7.1% compared to the same period last year. Life Science segment net sales decreased by 17.1%, while Clinical Diagnostics segment net sales increased by 1.7%. Gross margin was 53.1%. Net income for Q3 2023 was $106.3 million compared to a net loss of $162.8 million in Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
-
Rhea-AI Summary
Bio-Rad Laboratories to report Q3 2023 financial results on October 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
conferences earnings
-
Rhea-AI Summary
Bio-Rad Laboratories to participate in fireside chat event at Wells Fargo's Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
buyback
-
Rhea-AI Summary
Bio-Rad Laboratories, Inc. will report its financial results for Q2 2023 on August 3, 2023. A conference call will be held to discuss the results. A live webcast will also be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
Bio-Rad Laboratories' President and CEO, Norman Schwartz, will present a company overview at the Jefferies Healthcare Conference on June 8, 2023. The presentation will be followed by a Q&A session with participation from Bio-Rad's Executive Vice President and CFO Ilan Daskal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
-
Rhea-AI Summary
Bio-Rad Laboratories, Inc. will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on May 17, 2023. The event will be available for live webcast and replay on Bio-Rad's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.72%
Tags

FAQ

What is the current stock price of Bio-Rad Laboratories (BIO)?

The current stock price of Bio-Rad Laboratories (BIO) is $323.69 as of November 20, 2024.

What is the market cap of Bio-Rad Laboratories (BIO)?

The market cap of Bio-Rad Laboratories (BIO) is approximately 9.2B.

What does Bio-Rad Laboratories, Inc. specialize in?

Bio-Rad specializes in providing innovative tools and services for the life science research and clinical diagnostics markets.

When was Bio-Rad Laboratories founded?

Bio-Rad Laboratories was founded in 1952.

Where is Bio-Rad Laboratories headquartered?

Bio-Rad Laboratories is headquartered in Hercules, California.

What are the core business segments of Bio-Rad?

Bio-Rad's core business segments are Clinical Diagnostics and Life Sciences.

What percentage of Bio-Rad's sales come from the Clinical Diagnostics segment?

56% of Bio-Rad's sales come from the Clinical Diagnostics segment.

How many employees does Bio-Rad have?

Bio-Rad employs over 7,600 people.

What is Bio-Rad's involvement in the biopharmaceutical industry?

Bio-Rad develops and manufactures instruments and reagents used in biopharmaceutical production and owns 33% of Sartorius, a supplier specializing in biologics manufacturing technology.

What is Bio-Rad's market reach?

Bio-Rad serves over 100,000 research and industry customers worldwide with major markets in the Americas, Europe, Asia, and other regions.

What is the significance of Bio-Rad's ownership in Sartorius?

Bio-Rad's ownership in Sartorius enhances its biopharmaceutical offerings, particularly in single-use technology for biologics manufacturing.

How does Bio-Rad contribute to scientific research and development?

Bio-Rad advances scientific research and development by providing high-quality instruments, reagents, and test systems used in genomics, proteomics, drug discovery, food safety, and medical diagnostics.

Bio-Rad Laboratories, Inc.

NYSE:BIO

BIO Rankings

BIO Stock Data

9.20B
19.42M
15.58%
78.32%
2.33%
Medical Devices
Laboratory Analytical Instruments
Link
United States of America
HERCULES